CS
SYRE icon

Credit Suisse’s Spyre Therapeutics SYRE Stock Holding History

Credit Suisse’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$837K Buy
+22,056
New +$639K ﹤0.01% 2378
2022
Q3 		– Sell
-1
Closed – – 4279
2022
Q2 		$0 Buy
+1
New +$35 ﹤0.01% 4301
2021
Q1 		– Sell
-464
Closed -$91K – 4552
2020
Q4 		$91K Buy
+464
New +$96.2K ﹤0.01% 4193
2016
Q4 		– Sell
-400
Closed -$64K – 4225
2016
Q3 		$64K Buy
+400
New +$55.6K ﹤0.01% 3989

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Credit Suisse's SYRE Position: Q1 2024 in Review

Credit Suisse opened a new position in Spyre Therapeutics (SYRE) in Q1 2024: 22,056 shares worth $837K. The stake represents ﹤0.01% of the portfolio and ranks #2378 among its holdings. This is a return to the name: Credit Suisse previously reported a position in SYRE as recently as Q2 2022.

Credit Suisse first reported a position in SYRE in Q3 2016 and has held it in 4 quarters since. 103 funds tracked by Wall St. Rank hold SYRE as of Q1 2024.

  • Credit Suisse held 22,056 shares of Spyre Therapeutics worth $837K as of Q1 2024.
  • Spyre Therapeutics was a new Credit Suisse position in Q1 2024.
  • Spyre Therapeutics made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2378 holding.
  • Credit Suisse first reported a position in Spyre Therapeutics in Q3 2016 and has held it in 4 quarters since.
  • 103 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.